Last reviewed · How we verify
Epidermolysis bullosa
Approved treatments
- Filsuvez · Amryt Pharmaceuticals Dac
Filsuvez works by targeting the underlying cause of Epidermolysis bullosa to reduce skin blistering. - Filsuvez · Amryt Pharma
- Filsuvez · CSL Behring
Monoclonal antibody that inhibits activated Factor XII (FXIIa), preventing the generation of bradykinin which causes angioedema attacks.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Epidermolysis bullosa patent landscape — cliff calendar, originator estates, attackable patents
- Epidermolysis bullosa treatment landscape brief
- Epidermolysis bullosa treatment updates RSS
Frequently asked questions about Epidermolysis bullosa
What drugs treat Epidermolysis bullosa?
Tracked treatments include Filsuvez.
What is the treatment for Epidermolysis bullosa?
Standard treatment for Epidermolysis bullosa includes Filsuvez. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Epidermolysis bullosa patent cliff · Epidermolysis bullosa CI report
- Treatment: Filsuvez · Amryt Pharmaceuticals Dac
- Treatment: Filsuvez · Amryt Pharma
- Treatment: Filsuvez · CSL Behring
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing